Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Prelude Therapeutics Inc reported Q1 2026 revenue of $4.58M, a significant increase from $0.0 in Q1 2025, driven by an upfront payment from Incyte. The net loss narrowed to $(10.4) M from $(32.1) M YoY, with diluted EPS improving to $(0.13). The company initiated a Phase 1 trial for PRT12396 and executed a $100M exclusive option agreement with Incyte, with potential milestones of up to $775M. Prelude also raised approximately $90M in equity to support operations for the next year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments